Drug profile · INN
olanzapine
APO-OLANZAPINE ODT
olanzapine (APO-OLANZAPINE ODT) is a d2-like dopamine receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.
Drug details — olanzapine
- US status
- approved
- Class
- Nervous system (N05)
- Route
- INTRAMUSCULAR
- Patents
- 3
- Programs
- 10
- Data quality
- 0.89
Quick answer
olanzapine (APO-OLANZAPINE ODT) is a d2-like dopamine receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.
Key facts
Mechanism of action
D2-like dopamine receptor antagonist
Primary target: D2-like dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is olanzapine?
olanzapine (APO-OLANZAPINE ODT) is a d2-like dopamine receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.
What is the brand name for olanzapine?
APO-OLANZAPINE ODT is a marketed brand name for olanzapine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of olanzapine?
olanzapine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.